statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Siemens ended at new closing high of Rs 5,768, and formed long bullish candlestick pattern on the daily timeframe, while the trading volumes in last three sessions remained healthy.

Trade Spotlight | How to trade in Zydus Lifesciences, Hind Copper and Siemens today

Incred Equities estimates Mirabegron to be a $75-80 million opportunity for Zydus Lifesciences, as the company also enjoys a 180-day exclusivity period

Zydus Life gains over 3% on launch of bladder control drug

After witnessing consistent double-digit growth in branded formulations business in recent years, growth in the domestic formulation segment has moderated to high single digits

Steady US sales to bring a healthy quarter for pharma sector

USFDA inspected Zydus Lifesciences' Onco injectable manufacturing plant in Ahmedabad from March 18 to 27

Zydus Lifesciences up marginally despite 4 observations from USFDA

Earlier on 26 March, Zydus Life's shares surged after the company received tentative approval from the US Food and Drug Administration (FDA) for its Letermovir tablets.

US FDA issues 4 observations for Zydus Life's Ahmedabad injectable plant

Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1100 in its research report dated March 20, 2024.

Buy Zydus Lifesciences; target of Rs 1100: Sharekhan

The drug will target specific genetic mutations prevalent in certain types of cancers, paving the way for more tailored and effective treatment approach.

Zydus Lifesciences rises 2% on launch of cancer drug Olaparib

Linde India has seen a nice breakout of downward sloping resistance trendline adjoining highs of October 12, 2023 and February 19, 2024. The stock formed long bullish candlestick pattern on the daily charts with above average volumes.

Trade Spotlight | How to trade in Zydus Lifesciences, Godfrey Phillips, Linde India today

KR Choksey is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1006 in its research report dated March 06, 2024.

Buy Zydus Lifesciences; target of Rs 1006: KR Choksey

Zydus Lifesciences formed strong bullish candlestick pattern on the daily charts, with robust volumes, while on the monthly basis, it has continued run up for fourth consecutive month.

Trade Spotlight | How to trade in Zydus Lifesciences, HCL Tech, Apollo Hospitals today

Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. The firm's products portfolio includes active pharmaceutical ingredients, human formulations, and animal health & veterinary. It operates through the following segments: Pharmaceuticals and Consumer Products. The Pharmaceuticals segment represents the business of integrated pharmaceutical operations with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The Consumer Products segment represents the business of development, production, marketing, and distribution of differentiated health and wellness products. The company was founded by Ramanbhai B. Patel in 1952 and is headquartered in Ahmedabad, India.

Volume	822,882.00
52-Wk High	1,031.70
52-Wk Low	484.95

ZYDUSLIFE.NSE Zydus Lifesciences Ltd.

About

Feed

News

Sentiment

Fundamentals